<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00436228</url>
  </required_header>
  <id_info>
    <org_study_id>OPB107935</org_study_id>
    <nct_id>NCT00436228</nct_id>
  </id_info>
  <brief_title>To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug</brief_title>
  <official_title>An Open-Label, Randomized, Crossover Study to Estimate the Formulation Effect on the Relative Bioavailability of Single Dose Oral SB-742510 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment
      of respiratory infections.

      The purpose of this study is to estimate the bioavailability of four different formulations
      and to evaluate the safety of each of the four formulations
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Subjects</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible physician, based on medical evaluations
             performed at screening.

          -  Healthy adults between 18 and 60 years of age, inclusive.

          -  Body weight proportional to height.

          -  Capable of giving written informed consent.

          -  Female subjects must be of non-childbearing potential.

          -  QTc less than 450 msec at screening

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified on the screening history and physical
             or on the 12-lead surface electrocardiogram at screening or pre-dose.

          -  The subject has a positive pre-study alcohol/urine drug screen.

          -  History of regular use of tobacco, or nicotine-containing products.

          -  A positive pre-study HIV antibody, Hepatitis B surface antigen (HBsAg) or Hepatitis C
             antibody result within 3 months of screening.

          -  Use of certain prescription or non-prescription drugs, including vitamins, herbal and
             dietary supplements.

          -  An unwillingness to comply with lifestyle and/or dietary restrictions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2007</study_first_submitted>
  <study_first_submitted_qc>February 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>October 9, 2008</last_update_submitted>
  <last_update_submitted_qc>October 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>healthy volunteer,</keyword>
  <keyword>Bioavailability,</keyword>
  <keyword>safety</keyword>
  <keyword>Phase I,</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

